A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder
About this trial
This is an interventional treatment trial for Conduct Disorder focused on measuring conduct disorder, oppositional defiant disorder, disruptive behavior disorder not otherwise specified, ADHD, risperidone, antipsychotropic agents, children
Eligibility Criteria
Inclusion Criteria: Diagnosis of Conduct Disorder, Oppositional Defiant Disorder, or Disruptive Behavior Disorder not otherwise specified, by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), Axis I criteria (patients with conduct disorder who also meet DSM-IV criteria for Attention Deficit/Hyperactivity Disorder (AD/HD) are eligible) total rating of >=24 on the Nisonger Child Behavior Rating Form (N-CBRF) Conduct Problem Subscale Diagnosis of Mild Mental Retardation, Moderate Mental Retardation or Borderline Intellectual Functioning by DSM-IV Axis II criteria (represents intelligence quotients (IQs) ranging from 35 to 84) Vineland Adaptive Behavior Scale <=84. Exclusion Criteria: Diagnosis of Pervasive Development Disorder or Schizophrenia and/or Other Psychotic Disorders by DSM-IV criteria mental impairment caused by head injury seizure disorder currently requiring medication history of tardive dyskinesia (a complication of neuroleptic therapy involving involuntary movements of facial muscles) or neuroleptic malignant syndrome (a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness) known hypersensitivity, intolerance, or unresponsiveness to risperidone.